Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers

Trial Profile

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Olorinab (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Mar 2018 Data from this trial will be presented at the American Pain Society (APS) Annual Scientific Meeting 2018, according to an Arena Pharmaceuticals media release.
    • 29 Apr 2015 Status changed from recruiting to completed, as reported in an Arena Pharmaceuticals media release.
    • 29 Apr 2015 Positive results published in an Arena Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top